Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Bioorganic Chemistry|November 22, 2025
ProTide-enabled antibody-drug conjugates: A novel platform for the targeted delivery of phosphorylated drugsSofia Siciliano, Clizia Bernardi, Federica Finetti, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 7, 2020
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasisAdriana Carino, Michele Biagioli, Silvia Marchianò, et al.
Pharmacological Research|September 12, 2024
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseasesMichele Biagioli, Cristina Di Giorgio, Elva Morretta, et al.
Biochemical Pharmacology|March 21, 2025
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosisSilvia Marchianò, Michele Biagioli, Cristina Di Giorgio, et al.
ACS Omega|June 9, 2025
Exploring Boswellia serrata Triterpenes: A New Frontier in Leukemia Inhibitory Factor Receptor ModulationClaudia Finamore, Carmen Festa, Mattia Cammarota, et al.
Gut Microbes|March 19, 2026
A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitisMichele Biagioli, Cristina Di Giorgio, Silvia Marchianò, et al.
Cells|November 11, 2022
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic AdenocarcinomaCristina Di Giorgio, Antonio Lupia, Silvia Marchianò, et al.
Journal of Medicinal Chemistry|September 24, 2025
Harnessing the Estradienone Scaffold to Develop Dual GPBAR1 and LIFR Modulators for Liver FibrosisRosa De Gregorio, Federica Moraca, Pasquale Rapacciuolo, et al.
Journal of Medicinal Chemistry|October 9, 2024
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver FibrosisPasquale Rapacciuolo, Claudia Finamore, Cristina Di Giorgio, et al.
Biochemistry and Biophysics Reports|June 8, 2026
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapyCristina Di Giorgio, Michele Biagioli, Silvia Marchianò, et al.
Pageof 6